BACKGROUND: The use of proton pump inhibitors has been associated with an increased risk of hip fracture. We sought to further explore the relation between duration of exposure to proton pump inhibitors and osteoporosis-related fractures. METHODS: We used administrative claims data to identify patients with a fracture of the hip, vertebra or wrist between April 1996 and March 2004. Cases were each matched with 3 controls based on age, sex and comorbidities. We calculated adjusted odds ratios (OR) for the risk of hip fracture and all osteoporosis-related fractures for durations of proton pump inhibitor exposure ranging from 1 or more years to more than 7 years. RESULTS: We matched 15 792 cases of osteoporosis-related fractures with 47 289 controls. We did not detect a significant association between the overall risk of an osteoportic fracture and the use of proton pump inhibitors for durations of 6 years or less. However, exposure of 7 or more years was associated with increased risk of an osteoporosis-related fracture (adjusted OR 1.92, 95% confidence interval [CI] 1.16-3.18, p = 0.011). We also found an increased risk of hip fracture after 5 or more years of exposure (adjusted OR 1.62, 95% CI 1.02-2.58, p = 0.04), with even higher risk after 7 or more years exposure (adjusted OR 4.55, 95% CI 1.68-12.29, p = 0.002). INTERPRETATION: Use of proton pump inhibitors for 7 or more years is associated with a significantly increased risk of an osteoporosis-related fracture. There is an increased risk of hip fracture after 5 or more years exposure. Further study is required to determine the clinical importance of this finding and to determine the value of osteoprotective medications for patients with long-term use of proton pump inhibitors.
BACKGROUND: The use of proton pump inhibitors has been associated with an increased risk of hip fracture. We sought to further explore the relation between duration of exposure to proton pump inhibitors and osteoporosis-related fractures. METHODS: We used administrative claims data to identify patients with a fracture of the hip, vertebra or wrist between April 1996 and March 2004. Cases were each matched with 3 controls based on age, sex and comorbidities. We calculated adjusted odds ratios (OR) for the risk of hip fracture and all osteoporosis-related fractures for durations of proton pump inhibitor exposure ranging from 1 or more years to more than 7 years. RESULTS: We matched 15 792 cases of osteoporosis-related fractures with 47 289 controls. We did not detect a significant association between the overall risk of an osteoportic fracture and the use of proton pump inhibitors for durations of 6 years or less. However, exposure of 7 or more years was associated with increased risk of an osteoporosis-related fracture (adjusted OR 1.92, 95% confidence interval [CI] 1.16-3.18, p = 0.011). We also found an increased risk of hip fracture after 5 or more years of exposure (adjusted OR 1.62, 95% CI 1.02-2.58, p = 0.04), with even higher risk after 7 or more years exposure (adjusted OR 4.55, 95% CI 1.68-12.29, p = 0.002). INTERPRETATION: Use of proton pump inhibitors for 7 or more years is associated with a significantly increased risk of an osteoporosis-related fracture. There is an increased risk of hip fracture after 5 or more years exposure. Further study is required to determine the clinical importance of this finding and to determine the value of osteoprotective medications for patients with long-term use of proton pump inhibitors.
Authors: E Björnsson; H Abrahamsson; M Simrén; N Mattsson; C Jensen; P Agerforz; A Kilander Journal: Aliment Pharmacol Ther Date: 2006-09-15 Impact factor: 8.171
Authors: C Mel Wilcox; Jeroan Allison; Keith Benzuly; Marie Borum; Byron Cryer; Tilo Grosser; Richard Hunt; Uri Ladabaum; Angel Lanas; Harold Paulus; Carol Regueiro; Robert S Sandler; Lee Simon Journal: Clin Gastroenterol Hepatol Date: 2006-07-31 Impact factor: 11.382
Authors: J Brent Richards; Alexandra Papaioannou; Jonathan D Adachi; Lawrence Joseph; Heather E Whitson; Jerilynn C Prior; David Goltzman Journal: Arch Intern Med Date: 2007-01-22
Authors: Peggy M Cawthon; Stephanie L Harrison; Elizabeth Barrett-Connor; Howard A Fink; Jane A Cauley; Cora E Lewis; Eric S Orwoll; Steven R Cummings Journal: J Am Geriatr Soc Date: 2006-11 Impact factor: 5.562
Authors: Shelly L Gray; Andrea Z LaCroix; Joseph Larson; John Robbins; Jane A Cauley; JoAnn E Manson; Zhao Chen Journal: Arch Intern Med Date: 2010-05-10
Authors: T D Barrett; G Lagaud; P Wagaman; J M Freedman; W Yan; L Andries; M C Rizzolio; M F Morton; N P Shankley Journal: Br J Pharmacol Date: 2012-07 Impact factor: 8.739
Authors: Laura E Targownik; William D Leslie; K Shawn Davison; David Goltzman; Sophie A Jamal; Nancy Kreiger; Robert G Josse; Stephanie M Kaiser; Christopher S Kovacs; Jerilynn C Prior; Wei Zhou Journal: Am J Gastroenterol Date: 2012-07-10 Impact factor: 10.864
Authors: Daniel H Solomon; Susan J Diem; Kristine Ruppert; Yin Juan Lian; Chih-Chin Liu; Alyssa Wohlfart; Gail A Greendale; Joel S Finkelstein Journal: J Bone Miner Res Date: 2015-02 Impact factor: 6.741
Authors: John Danziger; Jeffrey H William; Daniel J Scott; Joon Lee; Li-wei Lehman; Roger G Mark; Michael D Howell; Leo A Celi; Kenneth J Mukamal Journal: Kidney Int Date: 2013-01-16 Impact factor: 10.612